AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15841664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 15841664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12423628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (an inhibitor of lipolysis) with GH
Number of subjects: 7
Study 12423628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox without GH
Number of subjects: 7
Study 12423628 — intervention group
Group type: COMPARATOR
Intervention: GH without Acipimox
Number of subjects: 7
Study 12423628 — intervention group
Group type: COMPARATOR
Intervention: Neither GH nor Acipimox
Number of subjects: 7
Study 9862828 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA 2 mg/kg/h
Number of subjects: 7
Study 9862828 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA 4 mg/kg/h
Number of subjects: 7
Study 9862828 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA 0.5 mg/kg/h
Number of subjects: 7
Study 9862828 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study 7537524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of all-trans retinoic acid (ATRA) and granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 18
Study 7537524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of ATRA, G-CSF, erythropoietin (Epo), and tocopherol
Number of subjects: 18
Study 7537524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of ATRA and cytokines
Number of subjects: 18
Study 2095747 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (drank three or more cups of coffee/day for two months)
Number of subjects: 21
Study 2095747 — intervention group
Group type: COMPARATOR
Intervention: Group B (abstained from coffee for two months)
Number of subjects: 21
Study 7033013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadiazine/trimethoprim (1 g daily for 10 days)
Number of subjects: 54
Study 7033013 — intervention group
Group type: COMPARATOR
Intervention: Sulphamethoxazole/trimethoprim (1.92 g B.I.D for 10 days)
Number of subjects: 54
Study 31568829 — intervention group
Group type: EXPERIMENTAL
Intervention: EMAT-guided management (n=114)
Number of subjects: 225
Study 31568829 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided management (n=111)
Number of subjects: 225
Study 31568829 — intervention group
Group type: EXPERIMENTAL
Intervention: EMAT-guided management in patients with predischarge %EMAT > 15% (n=85)
Number of subjects: 225
Study 31088559 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity mobile phone text message brief intervention
Number of subjects: 598
Study 31088559 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 598
Study 29605360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative treatment with paracetamol
Number of subjects: 0
Study 29605360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27468022 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.1 mg/kg i.m.)
Number of subjects: 6
Study 27468022 — intervention group
Group type: EXPERIMENTAL
Intervention: GV-26 acupuncture with electrical stimulation
Number of subjects: 6
Study 27468022 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (0.9% saline, at 0.1 ml/kg i.m.)
Number of subjects: 6
Study 24285605 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol septal ablation (ASA)
Number of subjects: 459
Study 23184162 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of fluoride gel using a toothbrush
Number of subjects: 10
Study 23184162 — intervention group
Group type: COMPARATOR
Intervention: Application of fluoride gel using a tray (control)
Number of subjects: 10
Study 20651607 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip position at 30° external rotation (H30)
Number of subjects: 10
Study 20651607 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip position at 50° external rotation (H50)
Number of subjects: 10
Study 20651607 — intervention group
Group type: COMPARATOR
Intervention: Hip position at neutral (H0)
Number of subjects: 10
Study 20651607 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexion at 60-90° (C3 and E3)
Number of subjects: 10
Study 17397734 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal hydration (using fortified balanced salt solution [BSS Plus])
Number of subjects: 80
Study 17397734 — intervention group
Group type: COMPARATOR
Intervention: No stromal hydration
Number of subjects: 80
Study 15718401 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip exercise (arm) at 60% maximum WR
Number of subjects: 6
Study 15718401 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee‐extensor exercise (leg) at 60% maximum WR
Number of subjects: 6
Study 15718401 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of shear rates at 60% maximum WR
Number of subjects: 6
Study 15718401 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of vessel diameter and shear rate
Number of subjects: 6
Study 11794191 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular assist device
Number of subjects: 129
Study 11794191 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 129
Study 9394977 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE-associated cutaneous diseases (AD and scabies)
Number of subjects: 0
Study 9394977 — intervention group
Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 0
Study 9394977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermopathic lymph node from AD patient
Number of subjects: 0
Study 9394977 — intervention group
Group type: COMPARATOR
Intervention: Normal lymphatic tissue
Number of subjects: 0
Study 7895789 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced visual cues during movement sequence
Number of subjects: 14
Study 7895789 — intervention group
Group type: COMPARATOR
Intervention: Fast movement sequence with visual cues
Number of subjects: 14
Study 3540329 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of the results of a screening instrument (the General Health Questionnaire)
Number of subjects: 0
Study 30925125 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus docetaxel
Number of subjects: 915
Study 30925125 — intervention group
Group type: COMPARATOR
Intervention: S‐1 alone
Number of subjects: 915
Study 28423233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 468
Study 28423233 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 468
Study 25782693 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telemonitored robotic-assisted therapy (HMP) combined with home exercise program (HEP) for 3 hours/day, 5 days/week for 8 weeks
Number of subjects: 99
Study 25782693 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program (HEP) only at identical dosage
Number of subjects: 99
Study 23887354 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir associated with tenofovir/emtricitabine or abacavir/lamivudine
Number of subjects: 39
Study 23887354 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir in protocol compliant population
Number of subjects: 39
Study 21823854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 62
Study 21823854 — intervention group
Group type: COMPARATOR
Intervention: Burch colposuspension
Number of subjects: 62
Study 19514485 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (close reduction and immobilization in a plastofit splint)
Number of subjects: 22
Study 19514485 — intervention group
Group type: COMPARATOR
Intervention: Operative treatment (percutaneous fixation by Kirschner‐wires)
Number of subjects: 22
Study 16705315 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV latent antibodies
Number of subjects: 256
Study 16705315 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV lytic antibodies
Number of subjects: 256
Study 16705315 — intervention group
Group type: COMPARATOR
Intervention: Anti-EBV antibodies
Number of subjects: 256
Study 16705315 — intervention group
Group type: COMPARATOR
Intervention: Antibody levels against EBV
Number of subjects: 256
Study 16705315 — intervention group
Group type: COMPARATOR
Intervention: Antibodies against KSHV (latent and lytic)
Number of subjects: 256
Study 15298070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0
Study 15298070 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 15298070 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer generation antidepressants
Number of subjects: 0
Study 11339515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular meloxicam (15 mg)
Number of subjects: 346
Study 11339515 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral meloxicam (15 mg)
Number of subjects: 346
Study 9401312 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonergic agents
Number of subjects: 0
Study 9401312 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 8260542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered immunoglobulins (IVIG)
Number of subjects: 116
Study 8260542 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVIG treatment)
Number of subjects: 116
Study 3920093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate
Number of subjects: 69
Study 3920093 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron chondroitinsulfuric acid complex
Number of subjects: 69
Study 3920093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin alone or associated with folinic acid and cobamamide
Number of subjects: 69
Study 31170306 — intervention group
Group type: EXPERIMENTAL
Intervention: K-SADS-PL-DSM-5-T
Number of subjects: 150
Study 28777459 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 607
Study 28777459 — intervention group
Group type: COMPARATOR
Intervention: Iopromide
Number of subjects: 607
Study 26304789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN) and Muscle Energy Technique (MET)
Number of subjects: 60
Study 26304789 — intervention group
Group type: COMPARATOR
Intervention: Muscle Energy Technique (MET)
Number of subjects: 60
Study 26304789 — intervention group
Group type: COMPARATOR
Intervention: Dry Needling (DN)
Number of subjects: 60
Study 24666774 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education intervention
Number of subjects: 20
Study 24666774 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 20
Study 22689290 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) taper
Number of subjects: 61
Study 22689290 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation pharmacotherapy or naturalistic follow-up after TMS taper
Number of subjects: 61
Study 20367092 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully etched test implants
Number of subjects: 112
Study 20367092 — intervention group
Group type: COMPARATOR
Intervention: Hybrid control implants
Number of subjects: 112
Study 18723908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 0.5 g/kg (low dose group)
Number of subjects: 38
Study 18723908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 1.0 g/kg (high dose group)
Number of subjects: 38
Study 18723908 — intervention group
Group type: COMPARATOR
Intervention: Both groups (0.5 g/kg and 1.0 g/kg)
Number of subjects: 38
Study 15944533 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative reconstruction with combined compensation
Number of subjects: 87
Study 15944533 — intervention group
Group type: COMPARATOR
Intervention: Filtered backprojection (FBP)
Number of subjects: 87
Study 12408208 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-peer intervention (face-to-face encouragement from peer interventionists)
Number of subjects: 0
Study 12408208 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-provider intervention (face-to-face encouragement from provider interventionists)
Number of subjects: 0
Study 12408208 — intervention group
Group type: COMPARATOR
Intervention: Standard care condition (open access to physical activity programming)
Number of subjects: 0
Study 10490161 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg x kg(‐1) clonidine p.o.
Number of subjects: 39
Study 10490161 — intervention group
Group type: COMPARATOR
Intervention: No clonidine
Number of subjects: 39
Study 8739021 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg daily
Number of subjects: 102
Study 8739021 — intervention group
Group type: EXPERIMENTAL
Intervention: Squalene 860 mg
Number of subjects: 102
Study 8739021 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin 10 mg + Squalene 860 mg)
Number of subjects: 102
Study 8739021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 8384980 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 10 million international units (MIU) of interferon alpha-2b (IFN) six times a week for eight weeks
Number of subjects: 126
Study 8384980 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 10 MIU IFN six times a week for four weeks followed by three times a week for an additional eight weeks
Number of subjects: 126
Study 8384980 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 10 MIU IFN six times a week for two weeks followed by three times a week for 12 weeks
Number of subjects: 126
Study 8384980 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 10 MIU IFN six times a week for eight weeks
Number of subjects: 126
Study 3700343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with lecithin and ergoloid mesylates
Number of subjects: 7
Study 29897597 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (20 Hz) rTMS
Number of subjects: 59
Study 29897597 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 59
Study 26969660 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (loading dose with 50 mg/kg over 10 min and then 15 mg/kg/h by continuous infusion)
Number of subjects: 84
Study 26969660 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 84
Study 26969660 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 84
Study 23337214 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide Cardiovascular Health Awareness Program (CHAP)
Number of subjects: 39
Study 23337214 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 communities without CHAP)
Number of subjects: 39
Study 21834964 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and weight cohort trials facility
Number of subjects: 20000
Study 21834964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing information as to the natural history of the condition and treatment as usual
Number of subjects: 20000
Study 19350305 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term chemoradiotherapy (RT/CTx) as standard treatment for locally advanced rectal cancer.
Number of subjects: 0
Study 19350305 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality controlled principles of radical surgery (partial vs total mesorectal excision) followed by adjuvant chemotherapy.
Number of subjects: 0
Study 17352947 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation for 8 weeks
Number of subjects: 33
Study 17352947 — intervention group
Group type: COMPARATOR
Intervention: Baseline (pre-treatment)
Number of subjects: 33
Study 17352947 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment
Number of subjects: 33
Study 17352947 — intervention group
Group type: COMPARATOR
Intervention: Dietary iron intake
Number of subjects: 33
Study 17352947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean corpuscular volume and hemoglobin
Number of subjects: 33
Study 15122749 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, initiated 8 weeks after onset of acute hepatitis.
Number of subjects: 30
Study 15122749 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, followed by interval IFN therapy (3 times weekly for 20 weeks).
Number of subjects: 30
Study 15122749 — intervention group
Group type: COMPARATOR
Intervention: Short-term therapy with natural IFN-alfa (6 million units) for 4 weeks, initiated after 1 year of observation.
Number of subjects: 30
Study 11345493 — intervention group
Group type: COMPARATOR
Intervention: J0 (no fire jacket)
Number of subjects: 6
Study 11345493 — intervention group
Group type: EXPERIMENTAL
Intervention: J1 (leather jacket)
Number of subjects: 6
Study 11345493 — intervention group
Group type: EXPERIMENTAL
Intervention: J3 (textile jacket without membrane)
Number of subjects: 6
Study 11345493 — intervention group
Group type: EXPERIMENTAL
Intervention: J5 (textile jacket with Kermel HTA)
Number of subjects: 6
Study 11345493 — intervention group
Group type: EXPERIMENTAL
Intervention: J2 (textile jacket with membrane)
Number of subjects: 6
Study 11345493 — intervention group
Group type: EXPERIMENTAL
Intervention: J4 (textile jacket with Kermel HTA)
Number of subjects: 6
Study 9257777 — intervention group
Group type: EXPERIMENTAL
Intervention: grepafloxacin (400 mg)
Number of subjects: 351
Study 9257777 — intervention group
Group type: COMPARATOR
Intervention: cefixime (400 mg)
Number of subjects: 351
Study 8314485 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 26
Study 8314485 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 26
Study 3534597 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy
Number of subjects: 0
Study 3534597 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy followed by definitive radiotherapy
Number of subjects: 0
Study 3534597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 30244988 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 140
Study 30244988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 26658703 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician empathy (PE)
Number of subjects: 71
Study 26658703 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM)
Number of subjects: 71
Study 26658703 — intervention group
Group type: EXPERIMENTAL
Intervention: Match between patients' preferred and perceived decision-making styles
Number of subjects: 71
Study 24411489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Formula (IF) - 1.89 g protein/100 kcal with α‐lactalbumin (ALAB) and LC‐PUFA
Number of subjects: 213
Study 24411489 — intervention group
Group type: COMPARATOR
Intervention: Control Formula (CF) - 2.30 g protein/100 kcal with standard whey and no LC‐PUFA
Number of subjects: 213
Study 22337145 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 151
Study 22337145 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 151
Study 22337145 — intervention group
Group type: COMPARATOR
Intervention: Pain education
Number of subjects: 151
Study 20423560 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic)
Number of subjects: 26
Study 20423560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18942247 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated ringer 20 ml/kg
Number of subjects: 60
Study 18942247 — intervention group
Group type: COMPARATOR
Intervention: 5% hypertonic saline 4 ml/kg followed by lactated ringer 10 ml/kg/hr
Number of subjects: 60
Study 16412917 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive anterior capsule polishing
Number of subjects: 54
Study 16412917 — intervention group
Group type: COMPARATOR
Intervention: No treatment (non-polishing)
Number of subjects: 54
Study 12519743 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin
Number of subjects: 20
Study 12519743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12119980 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-developed lead poisoning prevention program
Number of subjects: 0
Study 12119980 — intervention group
Group type: COMPARATOR
Intervention: Control census tracts
Number of subjects: 0
Study 8917053 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued treatment with antiepileptic drugs (AEDs)
Number of subjects: 409
Study 8917053 — intervention group
Group type: COMPARATOR
Intervention: Discontinued or reduced treatment before the occurrence of their first seizure
Number of subjects: 409
Study 8917053 — intervention group
Group type: COMPARATOR
Intervention: Discontinued treatment
Number of subjects: 409
Study 8917053 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort of patients
Number of subjects: 409
Study 1836615 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 0
Study 1836615 — intervention group
Group type: COMPARATOR
Intervention: Imipramine and Amitriptyline
Number of subjects: 0
Study 6287829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate (10 mg/kg body weight daily for 2 or 3 days)
Number of subjects: 0
Study 6287829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bephenium hydroxynaphthoate (2.5 g base) and piperazine citrate (2-3 g) given daily for 2 days
Number of subjects: 0
Study 6287829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6287829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate (2-day and 3-day courses)
Number of subjects: 0
Study 6287829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bephenium/piperazine regimen
Number of subjects: 0
Study 30068669 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sedation (1 mg/kg propofol intravenous)
Number of subjects: 78
Study 30068669 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 78
Study 29070044 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant everolimus plus letrozole for 18 weeks
Number of subjects: 40
Study 29070044 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant everolimus plus letrozole
Number of subjects: 40
Study 29070044 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil, epirubicin plus cyclophosphamide (FEC) for six cycles
Number of subjects: 40